BRISTOL MYERS SQUIBB
BMS-986446
This clinical trial’s goal is to determine the impact BMS-986446 on cognitive and functional decline in participants with early Alzheimer’s disease. BMS-986446 is an anti-MTBR Tau Monoclonal antibody.
Eligibility: Individuals who have mild cognitive impairment (MCI) or early Alzheimer’s disease.
Status: RECRUITING
ACUMEN
ACU193
This clinical trial examines ACU193 for how it affects individuals with mild Alzheimer’s disease or mild cognitive impairment (MCI). This new antibody binds to the Aβ-derived diffusible ligands (ADDLs), which are believed to increase memory problems and brain cell death.
Eligibility: Individuals with mild Alzheimer’s disease or mild cognitive impairment (MCI).
Status: RECRUITING
JANSSEN AND JANSSEN
JNJ-63733657
Focusing on early Alzheimer’s, this study tests the anti-tau antibody, JNJ-63733657, against a placebo, assessing its potential to slow disease progression. This study is for people who do not have an Alzheimer’s disease diagnosis or symptoms, rather they are at a risk for the condition.
Eligibility: Individuals that are healthy with risk of Alzheimer’s disease.
Status: RECRUITING
IPSEN
Dysport
In this clinical study, we are looking at the impact Dysport has on chronic and episodic migraines. The goal is to see if this Botulinum toxin injection reduces the number of days with migraines.
Eligibility: For both the chronic and episodic migraine studies, eligible individuals began having migraines before turning 50 years old, and is at least 18 years old.
Status: RECRUITING
SUVEN
Masupirdine
This clinical trial is testing Masupirdine‘s effectiveness on calming agitation that often affects those with Alzheimer’s disease. This oral medication is a selective antagonist of the 5-HT6 serotonin receptor.
Eligibility: Individuals with Alzheimer’s disease with untreated agitation.
Status: RECRUITING
LUNDBECK
Lu AG09222
This research explores the potential Lu AG09222 has to reduce migraine days more effectively than a placebo. Lu AG09222 is a anti-PACAP antibody that will inhibit PACAP.
Eligibility: Individuals who have not found relief with 2-4 other treatments, began having migraines before they turned 50 years old, and are between 18 and 65 years old.
Status: RECRUITING
COGNITO
HOPE
This study assesses the impact the COGNITO device has on slowing Alzheimer’s disease’s progression. We measure the effects the device’s visual and audio stimulation has on the participant’s daily activities and cognitive functions.
Eligibility: Individuals with mild to moderate Alzheimer’s disease.
Status: RECRUITING
HOFFMANN-LA ROCHE
PASEDENA
This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients.
Status: ACTIVE, NOT RECRUITING
EISAI
Clarity AD
Lecanemab antibody targets amyloid-beta plaques in the brain to potentially slow the progression of Alzheimer’s disease. This study examines its impact on cognitive function over 18 months, with an extension phase to monitor long-term safety and effects.
Status: ACTIVE, NOT RECRUITING
HOFFMANN-LA ROCHE
PADOVA
This trial evaluates Prasinezumab’s effectiveness on treating early Parkinson’s Disease by slowing disease progression and motor symptoms. This is a monoclonal antibody targeting alpha-synuclein aggregates, aiming to improve quality of life for patients. This is a 5-year extension study to PASEDENA.
Status: ACTIVE, NOT RECRUITING
